CA2808680A1 - Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin - Google Patents

Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin Download PDF

Info

Publication number
CA2808680A1
CA2808680A1 CA2808680A CA2808680A CA2808680A1 CA 2808680 A1 CA2808680 A1 CA 2808680A1 CA 2808680 A CA2808680 A CA 2808680A CA 2808680 A CA2808680 A CA 2808680A CA 2808680 A1 CA2808680 A1 CA 2808680A1
Authority
CA
Canada
Prior art keywords
et0h
dhm
alcohol
gabaar
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2808680A
Other languages
English (en)
French (fr)
Inventor
Jing Liang
Richard W. Olsen
Igor Spigelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2808680A1 publication Critical patent/CA2808680A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2808680A 2010-08-24 2011-08-23 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin Abandoned CA2808680A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37652810P 2010-08-24 2010-08-24
US61/376,528 2010-08-24
PCT/US2011/048749 WO2012027326A2 (en) 2010-08-24 2011-08-23 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin

Publications (1)

Publication Number Publication Date
CA2808680A1 true CA2808680A1 (en) 2012-03-01

Family

ID=45724009

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2808680A Abandoned CA2808680A1 (en) 2010-08-24 2011-08-23 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin

Country Status (14)

Country Link
US (1) US20130053435A1 (OSRAM)
EP (1) EP2608786A2 (OSRAM)
JP (1) JP2013536238A (OSRAM)
KR (1) KR20130098347A (OSRAM)
CN (1) CN103269699A (OSRAM)
AU (1) AU2011293556A1 (OSRAM)
BR (1) BR112013003946A2 (OSRAM)
CA (1) CA2808680A1 (OSRAM)
CL (1) CL2013000518A1 (OSRAM)
EA (1) EA201390217A1 (OSRAM)
MX (1) MX2013002162A (OSRAM)
PH (1) PH12013500293A1 (OSRAM)
SG (1) SG187771A1 (OSRAM)
WO (1) WO2012027326A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007853A1 (en) * 2012-07-03 2014-01-09 The Regents Of The University Of California Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system
CN103772338A (zh) * 2014-01-10 2014-05-07 吉首大学 真空脉动式制备二氢杨梅素的方法
AU2019249277A1 (en) * 2018-04-06 2020-10-22 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders
CN108567772A (zh) * 2018-07-24 2018-09-25 广西师范大学 二氢杨梅素的新用途
WO2020094669A1 (de) * 2018-11-05 2020-05-14 Evanium Healthcare Gmbh Alkohol-antidot
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
KR20220012903A (ko) * 2019-05-23 2022-02-04 이케이와이제이 컨설팅 투 엘엘씨 알코올-유발성 피부 안면홍조의 치료 및 완화를 위한 조성물 및 방법
GR1010117B (el) 2020-07-14 2021-11-08 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Διατροφικο συμπληρωμα για την απο του στοματος χορηγηση συνδυασμου διυδρομυρισετινης, χολινης και μιας ή περισσοτερων βιταμινων με αντιοξειδωτικη δραση, χρησιμων για τη φυσιολογικη λειτουργια του ηπατος
CN112546014B (zh) * 2020-12-15 2023-01-31 铜仁职业技术学院 一种中药解酒护肝泡腾片及其制备方法
CN113842461B (zh) * 2021-11-04 2023-08-11 杭州诺莘科技有限责任公司 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293825C (zh) 2002-08-30 2007-01-10 广州拜迪生物医药有限公司 二氢杨梅树皮素在制备食品、化妆品或药品中的应用
KR20040021927A (ko) 2002-09-06 2004-03-11 차재영 호깨나무와 홍삼 추출물을 이용한 건강 보조식품프로헤파-알지의 개발
CN101336978B (zh) * 2008-08-12 2013-01-30 西北农林科技大学 一种北枳椇总黄酮的提取方法
CN101336987B (zh) * 2008-08-12 2012-04-25 西北农林科技大学 一种枳椇总黄酮的制备方法

Also Published As

Publication number Publication date
US20130053435A1 (en) 2013-02-28
CL2013000518A1 (es) 2013-08-02
JP2013536238A (ja) 2013-09-19
PH12013500293A1 (en) 2013-03-25
WO2012027326A2 (en) 2012-03-01
EA201390217A1 (ru) 2013-12-30
SG187771A1 (en) 2013-03-28
KR20130098347A (ko) 2013-09-04
EP2608786A4 (en) 2013-07-03
AU2011293556A1 (en) 2013-02-28
EP2608786A2 (en) 2013-07-03
MX2013002162A (es) 2013-04-05
WO2012027326A9 (en) 2012-04-19
BR112013003946A2 (pt) 2016-07-12
CN103269699A (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
US20130053435A1 (en) Methods of Treating Alcohol Intoxication, Alcohol Use Disorders and Alcohol Abuse Which Comprises the Administration of Dihydromyricetin
Fernández et al. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam
Carlos Filho et al. Kappa-opioid receptors mediate the antidepressant-like activity of hesperidin in the mouse forced swimming test
Sun-Edelstein et al. Foods and supplements in the management of migraine headaches
AU2009206753B2 (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
Yan et al. The effect of Schisandra chinensis extracts on depression by noradrenergic, dopaminergic, GABAergic and glutamatergic systems in the forced swim test in mice
Cai et al. Antidepressant-like effects of penta-acetyl geniposide in chronic unpredictable mild stress-induced depression rat model: Involvement of inhibiting neuroinflammation in prefrontal cortex and regulating hypothalamic-pituitaryadrenal axis
Aburawi et al. Effect of ascorbic acid on mental depression drug therapy: clinical study
CN107530320A (zh) 肌肉脂肪化抑制用组合物
KR20110056278A (ko) 인슐린 민감성 강화제 및 항당뇨병제로서의 식물 추출물
EP4647078A2 (en) Novel association of gastrodia elata, citicoline, l-acetylcarnitine and vitamin b
US10799550B2 (en) Oral compositions comprising beta-escin for reducing acetaldehyde toxicity
Jai et al. Evidence against resveratrol as a viable therapy for the rescue of defective ΔF508 CFTR
Jiang et al. Nicotinamide riboside alleviates sweeteners-induced brain and cognitive impairments in immature mice
Afzal et al. Nutrition and Substance-Use Disorder
US20240173339A1 (en) Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid
RU2633484C2 (ru) Новое применение мелатонина
US11464756B1 (en) Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
Abdelkawy et al. Pharmacokinetics interaction of dapoxetine with different doses of green tea extract in male healthy volunteers using midazolam as CYP3A4 enzyme probe
HK1183444A (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
Chopra et al. Tocotrienol and cognitive dysfunction induced by alcohol
CN103338780A (zh) 含有腔昆布提取物和黑昆布提取物的用于正向变构调节gabaa-苯二氮杂*受体的组合物和用于产生镇静催眠效果的组合物
Antkiewicz-Michaluk et al. An endogenous neurotoxin, 1-benzyl-1, 2, 3, 4-tetrahydro-isoquinoline impairs of L-DOPA-induced behavioral and biochemical effects on dopamine system in rat
Caputo et al. GAMMA HYDROXYBUTYRIC ACID (GHB): A VALID PHARMACOLOGICAL OPPORTUNITY FOR THE TREATMENT OF ALCOHOL DEPENDENCE
HK1144772B (en) Protopanaxadiol-type ginsenoside compositions and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160824